Loading...
Market
Story
Ozempic, Wegovy Weight-Loss Drugs May Slow Ageing, Researchers Find
Aug 31, 2024, 05:28 AM
Recent scientific findings suggest that the weight-loss drug Ozempic, also known as semaglutide or Wegovy, may have the potential to slow down the biological ageing process. Researchers have hailed the drug for its 'remarkable' ability to treat the underlying causes of a range of diseases, which could extend beyond its initial use for weight loss. The drug is believed to curb the effects of ageing and has been described as offering a 'fountain of youth.' In addition to its anti-ageing potential, Ozempic is also noted for reducing the risk of death in overweight individuals with heart disease. These findings have sparked significant interest in the broader health benefits of weight-loss drugs.
View original story
Similar markets
Under 10% • 25%
10% to 20% • 25%
20% to 30% • 25%
Over 30% • 25%
Above 50% • 25%
30%-50% • 25%
10%-30% • 25%
Below 10% • 25%
Less than 10% • 25%
10% to 20% • 25%
20% to 30% • 25%
More than 30% • 25%
Zepbound gains >10% market share over Wegovy • 25%
Zepbound gains 0-10% market share over Wegovy • 25%
Wegovy maintains current market share • 25%
Wegovy gains market share over Zepbound • 25%
Increase by more than 10% • 25%
Increase by 0-10% • 25%
Decrease by 0-10% • 25%
Decrease by more than 10% • 25%
Increased Sales • 25%
Decreased Sales • 25%
No Significant Change • 25%
Product Recall • 25%
Less than 25% • 25%
25-35% • 25%
35-45% • 25%
More than 45% • 25%
Eli Lilly gains significant market share • 25%
Eli Lilly maintains current market share • 25%
Eli Lilly loses market share • 25%
No significant change • 25%
Significant increase (>10%) • 25%
Moderate increase (5-10%) • 25%
No significant change • 25%
Decrease • 25%
